Jeffrey S. Glenn's most recent trade in Eiger BioPharmaceuticals Inc was a trade of 28,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Eiger BioPharmaceuticals Inc | Jeffrey S Glenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 28,000 | 28,000 | - | - | Stock Option (Right to Buy) | |
Eiger BioPharmaceuticals Inc | Jeffrey S Glenn | Director | Purchase of securities on an exchange or from another person at price $ 1.28 per share. | 22 Dec 2022 | 100,000 | 182,355 (0%) | 0% | 1.3 | 127,950 | Common Stock |
Eiger BioPharmaceuticals Inc | Jeffrey S Glenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
Eiger BioPharmaceuticals Inc | Jeffrey S Glenn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 5,000 | 76,355 (0%) | 0% | 0 | Common Stock |